ClearPoint Neuro's stock has performed well over the past 4 months, supported by solid business fundamentals. Despite the move higher, ClearPoint's valuation is still modest, given the company's ...
ClearPoint Neuro (NASDAQ:CLPT) reported record first-quarter 2026 revenue and reaffirmed its full-year outlook, as management ...
SOLANA BEACH, CA / ACCESS Newswire / April 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...
SOLANA BEACH, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling company providing navigation and delivery to the brain, today ...
SOLANA BEACH, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today ...
Zacks Investment Research on MSN
Compared to estimates, ClearPoint Neuro (CLPT) Q1 earnings: A look at key metrics
ClearPoint Neuro, Inc. (CLPT) reported $12.13 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 43%. EPS of -$0.32 for the same period compares to -$0.22 a ...
ClearPoint Neuro reported total operating expenses of $11.3 million in the quarter. The company ended the period with $12.4 million in cash and cash equivalents. “Our 2025 fiscal year is off to a ...
An announcement from ClearPoint Neuro ( (CLPT) ) is now available.
ClearPoint Neuro, Inc. (CLPT) is scheduled to announce Q1 earnings results on Wednesday, May 13th, after market close. The consensus EPS estimate is -$0.27, and the consensus revenue estimate is ...
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.19 per share a year ago. These ...
SOLANA BEACH, CA / ACCESS Newswire / March 17, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...
Record Revenue Achieved Including 25% Organic Growth in Devices and 43% Overall Growth SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a globa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results